MedTrace Logo

Effect of Meibomian Gland Probing on Ocular Surface in Ocular Rosacea

NCT02735681 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2018-04-26

No results posted yet for this study

Summary

Meibomian glands (MG) are modified sebaceous glands associated with the tarsus (collagenous structural component) of the upper and lower eyelids. Meibomian glands produce lipid-based secretions which are an integral and stabilizing part of the tear film. In blepharitis and ocular rosacea (two known causes of obstructive meibomian gland dysfunction (o-MGD), inflammation of the lid margins causes blockage of the meibomian gland orifices, changes in glandular secretions, and dropout of the glands themselves. This limits the production, secretion, and quality of meibum. With less oil in the tear film, the aqueous portion of tears is not stable and evaporates quickly which leads to dry eye.

Conditions

  • Meibomian Gland Dysfunction

Interventions

PROCEDURE

meibomian gland probing

Investigator will do baseline (OSDI) questionnaires prior to probing as well as at 1 week (at home), 1 month, 3months, and 6 months at office visits.

PROCEDURE

Left eye Meibomian Gland Probing Control Group

There will be no probing in the left eye. This will be used as a control for the right eye.

Sponsors & Collaborators

  • University of Arkansas

    lead OTHER

Principal Investigators

  • Sunali Goyal, MD · University of Arkansas

  • Joshua Hardin, MD · University of Arkansas

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-02-01
Primary Completion
2018-03-28
Completion
2018-03-28

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02735681 on ClinicalTrials.gov